AMLX
What one share of Amylyx Pharmaceuticals holds
Pharmaceutical Preparations
Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases.
Amylyx Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.43 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.19 |
| Cash and investments | $2.25 |
| Book value | $2.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.04 | −$13.35 | $0.05 | −$11.41 | — | −$21.53 |
| 2022 | $0.38 | −$3.39 | $0.04 | −$3.12 | — | $5.12 |
| 2023 | $5.44 | $0.70 | $0.02 | $0.15 | — | $6.40 |
| 2024 | $1.28 | −$4.43 | $0.00 | −$2.46 | — | $2.40 |
| 2025 | $0.00 | −$1.53 | $0.00 | −$1.31 | — | $2.78 |